Sabby Management’s Coherus Oncology CHRS Stock Holding History

Sabby Management’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-1,336	Closed	-$2.83M	–	227
2017 Q1	$2.83M	Buy	1,336 +424	+46%	+$10.4K	0.15%	69
2016 Q4	$2.57M	Buy	+912	New	+$25.5K	0.15%	86

Other funds holding CHRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Sabby Management's CHRS Position: Q2 2017 in Review

Sabby Management sold out of Coherus Oncology (CHRS) in Q2 2017, closing a stake of 93,308 shares — an estimated $1.97M sold.

Sabby Management first reported a position in CHRS in Q2 2015 and held it in 3 quarters. The position peaked at $1.97M in Q1 2017. 106 funds tracked by Wall St. Rank hold CHRS as of Q2 2017.

Sabby Management reported no remaining Coherus Oncology position as of Q2 2017 after selling out during the quarter.
Sabby Management sold 93,308 Coherus Oncology shares in Q2 2017, an estimated $1.97M.
Sabby Management first reported a position in Coherus Oncology in Q2 2015 and held it in 3 quarters.
Sabby Management's Coherus Oncology position peaked at $1.97M in Q1 2017.
106 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2017.

Based on Sabby Management's 13F filing for Q2 2017, filed 14 Aug 2017.